Prime has been named as a finalist in the ‘Developer of the Year’ category at the 2023 HealthInvestor Awards, having been awarded the title for the past three years.
The HealthInvestor Awards promote excellence and recognise outstanding performance in the independent healthcare sector and attract over 1,200 guests each year to the JW Marriott Grosvenor House in London.
Prime’s submission focused on its work over the last 12 months, delivering commitment to ‘developing space for change’. This work is driving a pipeline of deals valued at £400m, raising the profile of healthcare within the property sector.
In 2022, while achieving record turnover Prime was proud to certify as a B Corporation, joining a global group of highly successful companies reinventing business by pursuing Purpose as well as Profit. Becoming a B Corp has been a long-term strategic objective for Prime, using lessons learnt from communities to positively evolve the health and care property sector.
Prime’s strength and character, as well as strong relationships with clients and contractor partners, ensured construction completed on seven schemes in 2022 and commenced on three new schemes. These include a new £30.5 million cancer diagnostic and treatment centre in Guildford. This complex, pioneering development will be delivered in partnership with GenesisCare and Royal Surrey NHS Foundation Trust, providing patients with access to ground-breaking technology not widely available in the UK.
Acting as an enabler to the cancer centre, construction of a new multi-storey car park started on the same site of Royal Surrey County Hospital, freeing up additional parking capacity for hospital visitors and patients who have long struggled with parking availability.
Prioritising access and expansion, a 1,000-space multi-storey park and ride opened in 2022 at the Adanac Health and Innovation Campus, reducing congestion in the city of Southampton and at University Hospital Southampton. Prime also began work on a Costa coffee shop adjacent to the park and ride, providing facilities to the campus’s growing number of users, and enabled plans for a Sterile Services Department (SSD). At present, the SSD and aseptic pharmacy serving UHS take up room at the hospital that could be given over to patient care but are both integral to the Trust and other local medical facilities. As a solution, Prime is developing a sophisticated, state-of-the-art building to house these services.
Leighton Chumbley, Chief Executive, said: “We’re delighted that our efforts in 2022 have been recognised by HealthInvestor. To be shortlisted for a fourth year in a row demonstrates our integrity and commitment so that our clients and partners can rely on us to deliver positive change in their health and care environments.
“Certifying as a B Corp in 2022 is a huge achievement and it allows us to create a much greater impact together than we can alone. Being a B Corp means using our ability as a business to create the world we want to see at the urgent speed required to meet the challenges of climate and social breakdown.”
Winners will be decided by an independent panel of high-profile judges and announced at a celebratory gala dinner on 7 June at the JW Marriott Grosvenor House, London.
